S.Biomedics KRX:304360KOSDAQ
에스바이오메딕스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, S.Biomedics reported revenue of ₩4.8bn, up 0.2% year on year, and an operating loss of ₩3.7bn. S.Biomedics (에스바이오메딕스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
S.Biomedics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.8bn | +0.2% | −₩3.7bn margin −76.5% | – |
| Q1 2026 | ₩4.4bn | -1.4% | −₩3.0bn margin −68.0% | – |
| Q4 2025 derived | ₩4.0bn | -9.4% | −₩2.7bn margin −66.4% | – |
| Q3 2025 | ₩3.2bn | -3.9% | −₩1.9bn margin −59.4% | – |
| Q2 2025 | ₩4.8bn | +45.7% | −₩2.0bn margin −42.6% | – |
| Q1 2025 | ₩4.5bn | +71.2% | −₩1.7bn margin −37.9% | – |
| Q4 2024 derived | ₩4.4bn | +19.0% | −₩1.1bn margin −24.9% | −₩1.5bn |
| Q3 2024 | ₩3.4bn | +49.7% | −₩1.3bn margin −39.4% | −₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
S.Biomedics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest S.Biomedics news Korean headlines
No articles yet.